Dynavax Technologies (Dynavax Technologies) Additional Paid-In Capital : $1,554.6 Mil(As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Additional Paid-In Capital?

Dynavax Technologies's quarterly additional paid-in capital increased from Jun. 2023 ($1,527.5 Mil) to Sep. 2023 ($1,541.5 Mil) and increased from Sep. 2023 ($1,541.5 Mil) to Dec. 2023 ($1,554.6 Mil).

Dynavax Technologies's annual additional paid-in capital increased from Dec. 2021 ($1,441.9 Mil) to Dec. 2022 ($1,510.5 Mil) and increased from Dec. 2022 ($1,510.5 Mil) to Dec. 2023 ($1,554.6 Mil).

Dynavax Technologies Additional Paid-In Capital Historical Data

The historical data trend for Dynavax Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Additional Paid-In Capital Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,229.42

1,352.37

1,441.87

1,510.52

1,554.63

Dynavax Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,510.52	1,516.33	1,527.54	1,541.55	1,554.63

Dynavax Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Dynavax Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (Dynavax Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Executives

Robert Janssen	officer: Chief Medical Officer and VP	C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack	officer: Senior Vice President	39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess	officer: Principal Accounting Officer	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer	officer: Co-President and Senior VP	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald	officer: SVP and CFO	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman	officer: Chief Science Officer and VP	C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach	officer: VP, CBO, and General Counsel	1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063